A ground-breaking study - the largest of its kind globally - has found children with multiple sclerosis (MS) have better outcomes if treated early and with the same high-efficacy therapies as adults.
There are a limited number of therapies approved for children with MS, with only one considered to be of high-efficacy - meaning highly effective.